Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 31;13(5):869-872.
doi: 10.21037/tp-24-7. Epub 2024 May 28.

Detection of pretreatment circulating tumor DNA as a biomarker of poor outcome in intermediate-risk rhabdomyosarcoma

Fariba Navid  1   2 , Jaclyn A Biegel  2   3
Affiliations
Editorial

Detection of pretreatment circulating tumor DNA as a biomarker of poor outcome in intermediate-risk rhabdomyosarcoma

Fariba Navid et al. Transl Pediatr. .
No abstract available

Keywords: Circulating tumor DNA (ctDNA); FOXO1 fusion; outcomes; rhabdomyosarcoma (RMS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-24-7/coif). The authors have no conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

References

    1. Perez EA, Kassira N, Cheung MC, et al. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 2011;170:e243-51. 10.1016/j.jss.2011.03.001 - DOI - PubMed
    1. Skapek SX, Ferrari A, Gupta AA, et al. Rhabdomyosarcoma. Nat Rev Dis Primers 2019;5:1. 10.1038/s41572-018-0051-2 - DOI - PMC - PubMed
    1. Shern JF, Selfe J, Izquierdo E, et al. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. J Clin Oncol 2021;39:2859-71. 10.1200/JCO.20.03060 - DOI - PMC - PubMed
    1. Arndt CAS, Bisogno G, Koscielniak E. Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev 2018;68:94-101. 10.1016/j.ctrv.2018.06.013 - DOI - PubMed
    1. Oberoi S, Choy E, Chen YL, et al. Trimodality Treatment of Extremity Soft Tissue Sarcoma: Where Do We Go Now? Curr Treat Options Oncol 2023;24:300-26. 10.1007/s11864-023-01059-2 - DOI - PubMed